Multi-enzyme mimetic iridium nanozymes-based thrombus microenvironment-modulated nanoplatform for enhanced thrombolytic therapy

Huang, Meng; Zhu, Yuda; Xin, Guang; Wang, Yilan; Li, Fan; Li, Shiyi; Dong, Yuman; Zhang, Kun; Feng, Lijuan; Tang, Li; Zhang, Boli; Huang, Wen

doi:10.1016/j.cej.2023.144156

Cited by 5 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We gathered published literature to compile a brief overview of the currently available measures for evaluating the toxicity of nanomaterials. In vitro cellular experiments are commonly employed to assess the toxicity of nanoparticles due to their low cost and simplicity, allowing for deeper investigation into the underlying molecular mechanisms [ 204 ]. Experiments that can be used to determine toxicity based on in vitro cell experiments include cell viability, apoptosis, mitochondrial dysfunction, oxidative stress, and genotoxicity [ 190 , 205 ].…”

Section: The Safety Analysis Of Nanozymementioning

confidence: 99%

Nanozyme as a rising star for metabolic disease management

Wang,

He,

Huang

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Nanozyme, characterized by outstanding and inherent enzyme-mimicking properties, have emerged as highly promising alternatives to natural enzymes owning to their exceptional attributes such as regulation of oxidative stress, convenient storage, adjustable catalytic activities, remarkable stability, and effortless scalability for large-scale production. Given the potent regulatory function of nanozymes on oxidative stress and coupled with the fact that reactive oxygen species (ROS) play a vital role in the occurrence and exacerbation of metabolic diseases, nanozyme offer a unique perspective for therapy through multifunctional activities, achieving essential results in the treatment of metabolic diseases by directly scavenging excess ROS or regulating pathologically related molecules. The rational design strategies, nanozyme-enabled therapeutic mechanisms at the cellular level, and the therapies of nanozyme for several typical metabolic diseases and underlying mechanisms are discussed, mainly including obesity, diabetes, cardiovascular disease, diabetic wound healing, and others. Finally, the pharmacokinetics, safety analysis, challenges, and outlooks for the application of nanozyme are also presented. This review will provide some instructive perspectives on nanozyme and promote the development of enzyme-mimicking strategies in metabolic disease therapy. Graphical Abstract

show abstract

Section: The Safety Analysis Of Nanozymementioning

confidence: 99%